3D Medicines, Inc. (1244) AI Stock Analysis

• Market Cap: HK$1.41B
• Dividend Yield: N/A
• Average Volume (3M): 296.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.83
• Revenue Growth: -31.34%
• EPS Growth: 67.95%
• Country: HK
• Employees: 191
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 258,177,000
• 10 Day Avg. Volume: 434,004
• 30 Day Avg. Volume: 296,568
• PEG Ratio: -0.15
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: HK$5.50 ▼(-5.01%Downside)

3D Medicines, Inc. exhibits strong technical momentum, which positively influences the stock score. However, significant financial and valuation challenges, such as negative earnings and reliance on external funding, weigh down the overall score. The absence of earnings call insights and corporate events limits additional context.

3D Medicines, Inc. Business Overview & Revenue Model

Company Description

3D Medicines, Inc. (1244) operates within the biotechnology sector, specializing in the research, development, and commercialization of innovative oncology therapies. The company focuses on utilizing advanced technologies to create targeted treatments aimed at improving patient outcomes in cancer care.

How the Company Makes Money

3D Medicines, Inc. generates revenue primarily through the sale of its proprietary oncology therapies. The company may also engage in strategic partnerships and collaborations with other biotechnology firms, pharmaceutical companies, and research institutions to develop and commercialize new drugs. Additionally, 3D Medicines might receive milestone payments and royalties from licensing agreements with other entities that utilize its technology or products. Another potential revenue stream could be government or private funding for research and development in the field of oncology.

3D Medicines, Inc. Financial Statement Overview

Summary

3D Medicines, Inc. shows significant revenue growth but faces profitability challenges with persistent losses and negative operational margins. While the balance sheet has improved, reliance on external financing and negative cash flows suggest ongoing financial and operational challenges.

Income Statement

The company shows significant revenue growth from 2020 to 2024, with a strong increase in total revenue. However, the net income remains negative, indicating persistent losses. Gross profit margin is high, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a strong cash position with substantial cash equivalents and short-term investments. However, the company has a negative equity position until 2022, which improved in later years. The debt-to-equity ratio is concerning due to high leverage in earlier years, but it has improved recently.

Cash Flow

Operating cash flow has been negative, showing challenges in generating cash from core operations. Free cash flow is consistently negative, reflecting high capital expenditures and operational challenges. Financing cash flow is positive, indicating reliance on external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	445.65M	634.95M	567.39M	60.26M	0.00
Gross Profit	371.74M	524.01M	525.18M	55.98M	0.00
EBITDA	-226.95M	-529.23M	-1.03B	-1.45B	-303.35M
Net Income	-182.66M	-524.70M	-1.02B	-1.43B	-635.38M
Balance Sheet
Total Assets	1.22B	1.43B	1.33B	1.06B	496.22M
Cash, Cash Equivalents and Short-Term Investments	840.98M	996.58M	942.03M	824.48M	414.26M
Total Debt	237.62M	282.43M	175.70M	58.74M	20.37M
Total Liabilities	512.54M	558.20M	436.65M	3.33B	1.77B
Stockholders Equity	785.06M	936.74M	943.00M	-2.24B	-1.27B
Cash Flow
Free Cash Flow	-255.94M	-150.74M	-332.76M	-433.46M	-289.48M
Operating Cash Flow	-210.58M	-144.41M	-278.78M	-377.08M	-278.33M
Investing Cash Flow	17.95M	-187.58M	-242.11M	-98.87M	-20.48M
Financing Cash Flow	-33.92M	304.51M	408.41M	840.08M	607.39M

3D Medicines, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Positive. The current price of 5.79 is above the 20-day moving average (MA) of 4.62, above the 50-day MA of 4.16, and above the 200-day MA of 3.28, indicating a bullish trend. The MACD of 0.43 indicates Negative momentum. The RSI at 80.31 is Negative, neither overbought nor oversold. The STOCH value of 93.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1244.

3D Medicines, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	65 Neutral	HK$1.47B	36.75	4.92%	―	38.48%	―
Sector *	60 Neutral	HK$16.12B	5.55	-7.44%	3.87%	11.55%	-28.15%
2126	59 Neutral	HK$1.23B	―	-41.34%	―	-10.78%	24.88%
1244	57 Neutral	HK$1.41B	―	-21.22%	―	-31.34%	67.95%
6628	54 Neutral	HK$743.37M	―	-32.59%	―	-79.65%	37.50%
6998	51 Neutral	HK$1.23B	―	-4.30%	―	―	92.45%
2137	45 Neutral	HK$1.41B	―	-17.41%	―	-100.00%	-176.44%

3D Medicines, Inc. Corporate Events

3D Medicines Inc. Strengthens Stability with Strategic Agreement

3D Medicines Inc. has announced a strategic cooperation agreement with Qingdao Hainuo, aimed at resolving ongoing legal disputes and fostering future collaboration. The agreement, valued at RMB98.0 million, led to the withdrawal of civil proceedings and the discharge of a Preservation Order, thereby enhancing the company’s operational and financial stability.

3D Medicines, Inc. Enhances Operational Stability Through Strategic Cooperation

3D Medicines, Inc. has entered into a Strategic Cooperation Agreement with Qingdao Hainuo, a substantial shareholder of its subsidiary, to discharge a Preservation Order imposed by the Qingdao Intermediate People’s Court. This agreement, valued at RMB98.0 million, aims to improve the company’s financial flexibility and operational efficiency by unfreezing bank accounts and facilitating smoother day-to-day operations, thereby reinforcing the company’s financial stability.

3D Medicines Inc. Announces Successful AGM Resolutions

3D Medicines Inc. announced the successful passing of all resolutions at its Annual General Meeting held on June 30, 2025. Key resolutions included the appointment of Mr. Zhu Jinqiao as a non-executive director and the re-election of independent directors, along with the authorization for the board to manage share allotments and repurchases. These developments are poised to impact the company’s governance structure and operational strategies positively.

3D Medicines Inc. Announces Board Composition and Committee Assignments

3D Medicines Inc. has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board has also established three committees: Audit, Remuneration, and Nomination, with specific directors assigned as members or chairpersons of these committees. This organizational structure aims to enhance corporate governance and operational efficiency, potentially impacting the company’s strategic direction and stakeholder relations.

3D Medicines Inc. Announces Board Changes with New Non-Executive Director Appointment

3D Medicines Inc. announced a change in its board of directors, with Mr. Zhu Pai retiring as a non-executive director to focus on other engagements. The board expressed gratitude for his contributions. Following his retirement, the company proposes appointing Mr. Zhu Jinqiao, who has extensive experience in investment and entrepreneurship consulting, as the new non-executive director. This transition may influence the company’s strategic direction, given Mr. Zhu Jinqiao’s notable background and achievements in the healthcare investment sector.

3D Medicines Inc. Announces Annual General Meeting to Discuss Key Resolutions

3D Medicines Inc. has announced its upcoming annual general meeting scheduled for June 30, 2025, in Beijing, where shareholders will consider various resolutions, including the adoption of the 2024 financial statements and the election and re-election of directors. The meeting will also address the re-appointment of the company’s auditor and authorize the board to manage director remuneration and share allotments, indicating a focus on strengthening governance and operational oversight.